4-(N,N-二甲基氨甲基)苯硼酸二甲基丁二醇酯盐酸盐 | 878197-87-6

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸酯
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(N,N-二甲基氨甲基)苯硼酸二甲基丁二醇酯盐酸盐
• 中文别名: 4-((N,N-二甲基氨基)甲基)苯硼酸频那醇酯
• 英文名称: N,N-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanamine
• 英文别名: dimethyl-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyl]-amine；N,N-dimethyl-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanamine
• CAS: 878197-87-6
• 化学式: C₁₅H₂₄BNO₂
• mdl: MFCD04971190
• 分子量: 261.172
• InChiKey: SATLWVSJANHADH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.79
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  21.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温环境下。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-((N,N-Dimethylamino)methyl)phenylboronic acid pinacol ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-((N,N-Dimethylamino)methyl)phenylboronic acid pinacol ester
CAS number: 878197-87-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C15H24BNO2
Molecular weight: 261.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(N,N-二甲基氨甲基)苯硼酸二甲基丁二醇酯盐酸盐 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium acetate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 2.5h， 生成 N-(5-(4-(4-((dimethylamino)methyl)phenyl)quinolin-6-yl)-2-chloropyridin-3-yl)-2,4-difluorobenzenesulfonamide
  参考文献：
  名称：

  基于结构的优化导致了NSC765844的发现，NSC765844是一种高效，毒性较小且口服有效的双重PI3K / mTOR抑制剂

  摘要：

  磷酸肌醇3-激酶（PI3K）家族是广泛的人类癌症中最常被激活的酶之一。因此，抑制PI3K代表了一种有前途的癌症治疗策略。在本文中，设计了一系列苄胺取代的芳基磺酰胺类化合物，并使用整合了重点文库设计和虚拟筛选的策略合成了PI3K / mTOR双重抑制剂，从而发现了13b（NSC765844）。化合物13b对PI3Kα，β，γ，δ和mTOR的IC 50分别具有1.3、1.8、1.5、3.8和3.8 nM的强酶抑制作用。通过体外细胞毒性筛选程序在NCI中进一步评估了13b。GI平均的广谱抗肿瘤活性发现针对大约60个人类肿瘤细胞系的50值为18.6nM。图13b显示了用于动物研究的有利的理化性质和优异的药代动力学特征。当在A549非小细胞肺癌异种移植和BEL7404人肝细胞癌异种移植模型中口服给药时，它可以显着抑制肿瘤的生长。基于其出色的体内功效和出色的药代动力学特征，13b已被选作有希望的抗癌药物候选物，用于进一步的临床前研究。

  DOI：

  10.1016/j.ejmech.2016.06.030
• 作为产物：
  描述：

  对溴甲苯 在 N-溴代丁二酰亚胺(NBS) 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 偶氮二异丁腈 、 potassium acetate 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 四氯化碳 、 水 、 乙腈 为溶剂， 反应 7.5h， 生成 4-(N,N-二甲基氨甲基)苯硼酸二甲基丁二醇酯盐酸盐
  参考文献：
  名称：

  基于结构的优化导致了NSC765844的发现，NSC765844是一种高效，毒性较小且口服有效的双重PI3K / mTOR抑制剂

  摘要：

  磷酸肌醇3-激酶（PI3K）家族是广泛的人类癌症中最常被激活的酶之一。因此，抑制PI3K代表了一种有前途的癌症治疗策略。在本文中，设计了一系列苄胺取代的芳基磺酰胺类化合物，并使用整合了重点文库设计和虚拟筛选的策略合成了PI3K / mTOR双重抑制剂，从而发现了13b（NSC765844）。化合物13b对PI3Kα，β，γ，δ和mTOR的IC 50分别具有1.3、1.8、1.5、3.8和3.8 nM的强酶抑制作用。通过体外细胞毒性筛选程序在NCI中进一步评估了13b。GI平均的广谱抗肿瘤活性发现针对大约60个人类肿瘤细胞系的50值为18.6nM。图13b显示了用于动物研究的有利的理化性质和优异的药代动力学特征。当在A549非小细胞肺癌异种移植和BEL7404人肝细胞癌异种移植模型中口服给药时，它可以显着抑制肿瘤的生长。基于其出色的体内功效和出色的药代动力学特征，13b已被选作有希望的抗癌药物候选物，用于进一步的临床前研究。

  DOI：

  10.1016/j.ejmech.2016.06.030

文献信息

• [EN] FLUORINATED 2,4-DIAMINOPYRIMIDINE COMPOUNDS AS MER TYROSINE KINASE (MERTK) INHIBITORS AND USES THEREOF<br/>[FR] COMPOSÉS DE 2,4-DIAMINOPYRIMIDINE FLUORÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA TYROSINE KINASE MER (MERTK) ET LEURS UTILISATIONS
  申请人：TRILLIUM THERAPEUTICS INC

  公开号：WO2019006548A1

  公开（公告）日：2019-01-10

  A class of fluorinated 2,4-diaminopyrimidine compounds of Formula (I) have been prepared for use in the treatment of cancers and other MERTK related disorders. (Formula (I))

  一类氟代2,4-二氨基嘧啶化合物的化学式（I）已经制备用于治疗癌症和其他与MERTK相关的疾病。 (化学式（I))
• Reductive Coupling between C–N and C–O Electrophiles
  作者：Rong-De He、Chun-Ling Li、Qiu-Quan Pan、Peng Guo、Xue-Yuan Liu、Xing-Zhong Shu

  DOI：10.1021/jacs.9b05224

  日期：2019.8.14

  The cross-electrophile reaction is a promising strategy for C-C bond formation. Recent studies have focused mainly on reactions with organic halides. Here we report a coupling reaction between C-N and C-O electrophiles that demonstrates the possibility of constructing a C-C bond via C-N and C-O cleavage. Several reactions between benzyl/aryl ammonium salts and vinyl/aryl C-O electrophiles have been

  交叉亲电反应是 CC 键形成的一个有前景的策略。最近的研究主要集中在与有机卤化物的反应上。在这里，我们报告了 CN 和 CO 亲电试剂之间的偶联反应，证明了通过 CN 和 CO 裂解构建 CC 键的可能性。已经研究了苄基/芳基铵盐和乙烯基/芳基 CO 亲电试剂之间的几种反应。初步机理研究表明，苄基铵是通过自由基机制活化的。
• SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS
  申请人：Su Wei-Guo

  公开号：US20140121200A1

  公开（公告）日：2014-05-01

  Provided are pyridopyrazine compounds of formula (1), pharmaceutical compositions thereof and methods of use therefore, wherein R 1 , R 2 , R 3 , R 4 and m are as defined in the specification.

  提供了式（1）的吡啶吡嗪化合物，以及其药物组合物和使用方法，其中R1、R2、R3、R4和m如规范中所定义。
• [EN] SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS<br/>[FR] BENZAZINONES SUBSTITUÉS À UTILISER EN TANT QUE COMPOSÉS ANTIBACTÉRIENS
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017098440A1

  公开（公告）日：2017-06-15

  The present invention relates to LpxC antibacterial compounds of Formula (1A), corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions:, compound preparation, treatment methods and uses for bacterial infections, especially those caused by gram-negative bacteria.

  该发明涉及Formula (1A)的LpxC抗菌化合物，其相应的药学上可接受的盐，相应的药物组合物，化合物制备，细菌感染的治疗方法和用途，特别是由革兰氏阴性细菌引起的感染。
• Optimization of an Imidazo[1,2-<i>a</i>]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with <i>In Vivo</i> Efficacy
  作者：William McCoull、Scott Boyd、Martin R. Brown、Muireann Coen、Olga Collingwood、Nichola L. Davies、Ann Doherty、Gary Fairley、Kristin Goldberg、Elizabeth Hardaker、Guang He、Edward J. Hennessy、Philip Hopcroft、George Hodgson、Anne Jackson、Xiefeng Jiang、Ankur Karmokar、Anne-Laure Lainé、Nicola Lindsay、Yumeng Mao、Roshini Markandu、Lindsay McMurray、Neville McLean、Lorraine Mooney、Helen Musgrove、J. Willem M. Nissink、Alexander Pflug、Venkatesh Pilla Reddy、Philip B. Rawlins、Emma Rivers、Marianne Schimpl、Graham F. Smith、Sharon Tentarelli、Jon Travers、Robert I. Troup、Josephine Walton、Cheng Wang、Stephen Wilkinson、Beth Williamson、Jon Winter-Holt、Dejian Yang、Yuting Zheng、Qianxiu Zhu、Paul D. Smith

  DOI：10.1021/acs.jmedchem.1c00920

  日期：2021.9.23

  to improve potency and reduce lipophilicity, resulting in a highly selective in vivo probe compound 32. We demonstrated dose-dependent in vivo efficacy and target engagement in Mer- and Axl-dependent efficacy models using two structurally differentiated and selective dual Mer/Axl inhibitors. Additionally, in vivo efficacy was observed in a preclinical MC38 immuno-oncology model in combination with anti-PD1

  Mer 和 Axl 激酶的抑制被认为是通过恢复肿瘤微环境中的先天免疫反应来提高当前免疫肿瘤治疗效果的潜在方法。需要高度选择性的双 Mer/Axl 激酶抑制剂来验证这一假设。从 DNA 编码文库筛选的命中开始，我们使用基于结构的化合物设计优化了咪唑并[1,2- a ]吡啶系列，以提高效力并降低亲脂性，从而产生了高度选择性的体内探针化合物32 。我们使用两种结构差异化和选择性的双 Mer/Axl 抑制剂在 Mer 和 Axl 依赖性功效模型中证明了剂量依赖性体内功效和靶点参与。此外，在临床前 MC38 免疫肿瘤学模型中观察到与抗 PD1 抗体和电离辐射相结合的体内疗效。